With its new partnership with Chugai Pharmaceutical Co., Araris takes another step forward in the development of innovative cancer therapies.
Araris Biotech AG, a successful spin-off from PSI, has made another significant advancement in its corporate development. The company today announced a research collaboration with Chugai Pharmaceutical Co., Ltd. As part of the agreement, Araris will use its proprietary AraLinQ™ linker-conjugation technology to develop novel antibody-drug conjugates (ADCs). This technology enables the efficient attachment of multiple therapeutic payloads to an antibody molecule in a single step, without the need for prior antibody modification.
This collaboration highlights the significant potential of Araris' innovative ADC approach, which aims to improve the efficacy and tolerability of cancer therapies. Under the agreement, Araris will receive an upfront payment and potential milestone payments of up to USD 780 million, as well as royalties on net product sales. This demonstrates the trust leading companies have in Araris' technology and underscores that this PSI spin-off is a pioneering company in the field of cancer therapy.
The collaboration with Chugai represents Araris’ second partnership with a major pharmaceutical company, further highlighting the attractiveness of the AraLinQ™ platform. Araris once again proves that it is not only an innovator in biotechnology but also a valued partner in the pharmaceutical industry.
The spin-off Araris Biotech, born from the PSI Founder Fellowship program, is a prime example of the success of this initiative, which allows researchers and entrepreneurs to transform their business ideas into market-leading companies.
We are proud to support Araris on its journey and look forward to continuing to create an environment that fosters the success of spin-offs like Araris.
More information:
